Top Gilead can­cer re­searcher jumps to a start­up as Dan Chen ex­its; Arde­lyx gets that CRL we've been wait­ing for

Chris Taki­mo­to, the for­mer CMO at Forty Sev­en who com­plet­ed a stint as SVP of on­col­o­gy R&D at Gilead af­ter the buy­out, is mov­ing on. He’s been giv­en the CMO spot at IGM Bio­sciences.

Taki­mo­to is tak­ing the place of Dan Chen, a for­mer top on­col­o­gy re­searcher at Genen­tech who played a sig­nif­i­cant role in the de­vel­op­ment of Tecen­triq. Chen is mov­ing from his top re­search post at IGM to con­sul­tant, with IGM ex­ecs of­fer­ing best wish­es for the next stage of his ca­reer and thanks for “man­ag­ing the ini­tial dose es­ca­la­tion por­tion of our Phase 1 clin­i­cal tri­al of IGM-2323, our CD20 x CD3 T cell en­gager IgM an­ti­body for non-Hodgkin’s lym­phoma, and suc­cess­ful­ly launch­ing our Phase 1 clin­i­cal tri­al of IGM-8444, our Death Re­cep­tor 5 ag­o­nist IGM an­ti­body for sol­id and liq­uid tu­mors.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER